Verified factor-similar pair

DES vs XMVM

These two ETFs meet the same FF6 US comparison criteria: US-listed equity ETFs, the same USD model basis, at least one material non-market factor, and 100% overlap in statistically significant material factor exposure.

SMB HML RMW
Similarity score
87
Verified similar

The score combines exposure-level distance, factor-vector shape, market-beta closeness, and a small backtested relative-Sharpe term.

Quick Read

  • XMVM has the higher backtested relative Sharpe (0.999 vs 0.895).
  • DES has the lower published fee (0.38% vs 0.41%).
  • XMVM is cheaper on dividend valuation (98 vs 136, where 100 is each fund's historical median).
  • DES has the stronger regression fit (adjusted R-squared 0.941 vs 0.899).

These are screening signals, not a complete review of portfolio construction, turnover, taxes, or trading quality.

DES

WisdomTree U.S. SmallCap Dividend Fund
SMB HML RMW
Adj. R2
0.941
Rel. Sharpe
0.895
Mkt beta
0.90
AUM
US$2.0B
MER
0.38%
Valuation
136

XMVM

Invesco S&P MidCap Value with Momentum ETF
SMB HML RMW
Adj. R2
0.899
Rel. Sharpe
0.999
Mkt beta
0.98
AUM
US$435M
MER
0.41%
Valuation
98

Factor Exposure Match

Blue bars compare raw factor beta magnitude. Green bars compare absolute t-stat strength. Dim bars indicate the t-stat is below 1.96.

SMB
DES
+0.75
|t|
+18.4
XMVM
+0.46
|t|
+9.4
diff +0.29
HML
DES
+0.39
|t|
+9.9
XMVM
+0.34
|t|
+7.0
diff +0.06
RMW
DES
+0.28
|t|
+5.7
XMVM
+0.25
|t|
+4.3
diff +0.02
CMA
DES
+0.10
|t|
+1.6
XMVM
+0.04
|t|
+0.6
diff +0.06
UMD
DES
-0.10
|t|
-4.2
XMVM
-0.06
|t|
-2.1
diff -0.04

Why This Pair Matches

Exposure level
86
Exposure shape
99
Mkt beta diff
0.08
Rel. Sharpe diff
0.104

This comparison focuses on measured factor exposure. It does not compare holdings methodology, turnover, tax handling, or issuer process. Backtested relative Sharpe is a secondary signal rather than a stand-alone forecast. See methodology.

DES fund page XMVM fund page US ETF Leaders US Universe
Important context

VerifiedBeta publishes educational ETF research, not personalized investment advice, portfolio management, or security recommendations. Funds that screen well here can still be unsuitable for your objectives, taxes, liquidity needs, or constraints. Review fund documents, methodology assumptions, and your own circumstances before acting. See the full disclaimer.